Home > Browse Issues > Vol.44 No.12

Recent Advances of RORs in Cancer


ZHAO Xin1,2, DING Lin2, CHEN Yu-Syuan2, HU Qinghua1 *

( 1 School of Pharmacy, China Pharmaceutical University, Nanjing 211198, China; 2 Shanghai Henlius Biotech, Inc., Shanghai Innovation Center, Shanghai 200233, China)
Abstract:

The ROR family contains ROR1 and ROR2, which are Wnt receptors that are critical for nonclassical Wnt signaling pathways and are associated with cancer cell proliferation, survival, invasion, metastasis, and treatment resistance. RORs are less expressed in healthy adult tissues, but are overexpressed in several type of cancers. Interestingly, the two RORs may play different roles in tumors, with ROR1 always promoting tumorigenesis and ROR2 promoting or inhibiting tumor progression in different tumor types. This review summarizes the structural characteristics of RORs and its expression in different tissues. In addition, it reviews the biological processes and signaling pathways regulated by RORs to explain its important role in cancer. Finally, the biological drugs of targeting RORs in clinical trials of cancer therapies were summarized, including monoclonal antibodies, bispecific antibody and antibody-drug conjugate, etc


CSTR: 32200.14.cjcb.2022.12.0014